AAP
DYN icon

Arax Advisory Partners’s Dyne Therapeutics DYN Stock Holding History

Arax Advisory Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.1K Buy
+997
New +$18.5K ﹤0.01% 3894
2026
Q1 		– Sell
-18
Closed -$352 – 3946
2025
Q4 		$352 Sell
18
-465
-96% -$8.81K ﹤0.01% 3655
2025
Q3 		$6.11K Buy
483
+253
+110% +$2.89K ﹤0.01% 2805
2025
Q2 		$2.19K Hold
230
– – ﹤0.01% 2545
2025
Q1 		$2.41K Sell
230
-20
-8% -$286 ﹤0.01% 2015
2024
Q4 		$5.89K Hold
250
– – ﹤0.01% 1684
2024
Q3 		$8.98K Hold
250
– – ﹤0.01% 1468
2024
Q2 		$8.82K Buy
250
+20
+9% +$581 ﹤0.01% 1329
2024
Q1 		$6.53K Hold
230
– – ﹤0.01% 858
2023
Q4 		$3.06K Buy
+230
New +$2.25K ﹤0.01% 966

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Arax Advisory Partners's DYN Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 997 shares worth $22.1K. The stake represents ﹤0.01% of the portfolio and ranks #3894 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in DYN as recently as Q4 2025.

Arax Advisory Partners first reported a position in DYN in Q4 2023 and has held it in 10 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Arax Advisory Partners held 997 shares of Dyne Therapeutics worth $22.1K as of Q2 2026.
  • Dyne Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3894 holding.
  • Arax Advisory Partners first reported a position in Dyne Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.